Physician
Oncology
Dr. Svetislava J. Vukelja, MD
|
|
Give Review
Svetislava Vukelja is an expert in the field of Oncology. She studied medicine at Uniformed Services University of the Health Sciences. Uniformed Services University of the Health Sciences has a rank of 72 in research and a 47 in primary care She received awards:"Meaningful Use Stage 1 Certification" and "Super Doctor". Doctor Svetislava J. Vukelja, MD is a published physician. She has 39 publications published. The most current publication "High-dose cyclophosphamide, etoposide and carboplatin with autologous bone marrow support for metastatic breast cancer: long-term results." Svetislava J. Vukelja, MD is registered with Medicare and accepts Medicare payments.
Publications
- Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Ca...
- Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast Cancer patients.
- Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast Cancer: a single-group, open-label, phase 2 study.
- Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast Cancer after prior H...
- Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adju...
- Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube Cancer.
- Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent Lymphoma.
- Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research...
- Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast Cancer previously treated with every-3-week taxane therapy.
- Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancy.
- Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal Cancer.
- Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast Cancer undergoing adjuvant or neoadjuvant chemotherapy.
- Phase II trial of gemcitabine plus trastuzumab in metastatic breast Cancer patients previously treated with chemotherapy: preliminary results.
- Idarubicin-induced pigmentary changes of the nails.
- Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.
- Angiofollicular lymph node hyperplasia (Castleman''s Disease).
- Unusual serpentine hyperpigmentation associated with 5-fluorouracil. Case report and review of cutaneous manifestations associated with Systemic 5-fluorouracil.
- Paclitaxel-induced radiation recall dermatitis.
- Chemotherapy of disseminated Merkel-cell Carcinoma.
- High-dose cyclophosphamide, etoposide and carboplatin with autologous bone marrow support for metastatic breast Cancer: long-term results.
- Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere.
- Detailed Analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
- Cellular immune profile of patients with advanced Cancer before and after taxane treatment.
- Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding ...
- Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients...
- Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast Cancer: phase III trial results.
- Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung Cancer.
- Phase I and pharmacokinetic study of the dolastatin-15 Analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanc...
- Survival benefit with capecitabine/docetaxel versus docetaxel alone: Analysis of therapy in a randomized phase III trial.
- Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast Cancer.
- The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast Cancer.
- Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal Cancer.
- Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast Cancer.
- Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell Carcinoma of the urothelium.
- Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast Cancer: report of a Tamoxifen Exemestan...
- Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast Cancer.
- Determination of oestrogen-receptor status and ERBB2 status of Breast carcinoma: a gene-expression profiling study.
- Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid ...
Schools
Usuhs F E Hebert Sch Of Med
Walter Reed Army Med Center
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
Uniformed Services University of the Health Sciences
Drug Facts
| NPI NUMBER | 1851335442 | |
| NPPES Provider LastName | VUKELJA | |
| NPPES Provider FirstName | SVETISLAVA | |
| NPPES Provider ZIPCode | 75702 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology | |
| Total Claim Count | 1842.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 121.0 | |
| Percent Opioid Claims | 6.57 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1851335442 |
| Last Name Of The Provider | VUKELJA |
| First Name Of The Provider | SVETISLAVA |
| View All |
Similar Doctors
|
|
Dr. Frank T. Ward, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arielle S. Lee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Y. Ashigbi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert M. Droder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Manmeet Mangat, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shail Dalal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas F. Gregory, MD |
|
|
Dr. Marian F. Fagan, MD |
|
|
Dr. Hugh E. Tobin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven R. Sanchez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donald A. Richards, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles D. Haas, MD
This Doctor is OpenDoctor Recommended.
|